<p>Small cell lung cancer (SCLC) is an aggressive disease with poor outcomes and limited treatment options. Recent studies have identified transcriptionally defined subsets of SCLC that may allow for the personalization of treatment. Here we use transcriptomic sequencing and methylation profiling (RRBS) of biopsy and cfDNA to develop a highly accurate DNA methylation-based classifier to distinguish SCLC subtypes. These results demonstrate the clinical feasibility of molecular subtyping of SCLC.</p>

Transcriptomic and Epigenetic Profiling of SCLC Patient Samples

Small Cell Lung Carcinoma study with Bisulfite-Seq, RNA-Seq data on dbGaP (181 participants)